Trial Profile

The Efficacy of T-regulatory Cell Depletion with E7777 Combined with Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II Study

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denileukin diftitox (Primary) ; Pembrolizumab (Primary)
Indications Cervical cancer; Endometrial cancer; Gynaecological cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions

Most Recent Events

11 Nov 2024 According to a Citius Pharmaceuticals Inc Media Release, this trial is nearing completion with 3 remaining subjects to be enrolled.
11 Nov 2024 Results presented in the Citius Pharmaceuticals Inc. Media Release.
01 Nov 2022 According to Citius Pharmaceuticals Inc media release, first patient enrolled.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com